Lido Advisors’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $21.6M | Buy |
43,094
+3,116
| +8% | +$1.5M | 0.06% | 215 |
|
|
2026
Q1 | $19.7M | Sell |
39,978
-4,116
| -9% | -$2.23M | 0.06% | 206 |
|
|
2025
Q4 | $22.9M | Buy |
44,094
+410
| +0.9% | +$232K | 0.07% | 181 |
|
|
2025
Q3 | $21.2M | Buy |
43,684
+9,269
| +27% | +$4.31M | 0.07% | 181 |
|
|
2025
Q2 | $14M | Buy |
34,415
+1,935
| +6% | +$809K | 0.05% | 203 |
|
|
2025
Q1 | $16.2M | Buy |
32,480
+8,019
| +33% | +$4.34M | 0.07% | 166 |
|
|
2024
Q4 | $12.7M | Buy |
24,461
+2,934
| +14% | +$1.61M | 0.06% | 188 |
|
|
2024
Q3 | $13.3M | Sell |
21,527
-543
| -2% | -$321K | 0.07% | 165 |
|
|
2024
Q2 | $12.2M | Buy |
22,070
+96
| +0.4% | +$55K | 0.07% | 153 |
|
|
2024
Q1 | $12.8M | Sell |
21,974
-252
| -1% | -$141K | 0.08% | 137 |
|
|
2023
Q4 | $11.8M | Buy |
22,226
+723
| +3% | +$350K | 0.08% | 137 |
|
|
2023
Q3 | $10.9M | Buy |
21,503
+479
| +2% | +$255K | 0.08% | 130 |
|
|
2023
Q2 | $11M | Buy |
21,024
+1,635
| +8% | +$882K | 0.08% | 141 |
|
|
2023
Q1 | $11.2M | Buy |
19,389
+7,779
| +67% | +$4.38M | 0.11% | 114 |
|
|
2022
Q4 | $6.39M | Buy |
11,610
+864
| +8% | +$458K | 0.08% | 136 |
|
|
2022
Q3 | $5.45M | Sell |
10,746
-1,963
| -15% | -$1.1M | 0.07% | 141 |
|
|
2022
Q2 | $6.91M | Sell |
12,709
-1,765
| -12% | -$971K | 0.09% | 108 |
|
|
2022
Q1 | $8.55M | Buy |
14,474
+3,888
| +37% | +$2.23M | 0.1% | 107 |
|
|
2021
Q4 | $7.06M | Buy |
10,586
+2,084
| +25% | +$1.3M | 0.08% | 132 |
|
|
2021
Q3 | $4.86M | Buy |
8,502
+1,198
| +16% | +$658K | 0.07% | 159 |
|
|
2021
Q2 | $3.69M | Sell |
7,304
-1,465
| -17% | -$691K | 0.05% | 185 |
|
|
2021
Q1 | $4M | Buy |
8,769
+1,920
| +28% | +$916K | 0.07% | 160 |
|
|
2020
Q4 | $3.19M | Sell |
6,849
-1,111
| -14% | -$521K | 0.07% | 161 |
|
|
2020
Q3 | $3.52M | Sell |
7,960
-263
| -3% | -$109K | 0.09% | 123 |
|
|
2020
Q2 | $2.98M | Sell |
8,223
-1,041
| -11% | -$349K | 0.09% | 126 |
|
|
2020
Q1 | $2.63M | Buy |
9,264
+337
| +4% | +$106K | 0.11% | 114 |
|
|
2019
Q4 | $2.9M | Buy |
8,927
+1,464
| +20% | +$444K | 0.12% | 115 |
|
|
2019
Q3 | $2.17M | Buy |
7,463
+265
| +4% | +$75.9K | 0.11% | 115 |
|
|
2019
Q2 | $2.12M | Buy |
7,198
+10
| +0.1% | +$2.75K | 0.12% | 107 |
|
|
2019
Q1 | $1.97M | Sell |
7,188
-105
| -1% | -$26.1K | 0.13% | 107 |
|
|
2018
Q4 | $1.63M | Buy |
7,293
+839
| +13% | +$197K | 0.16% | 89 |
|
|
2018
Q3 | $1.58M | Buy |
6,454
+780
| +14% | +$179K | 0.15% | 89 |
|
|
2018
Q2 | $1.18M | Buy |
5,674
+720
| +15% | +$153K | 0.14% | 97 |
|
|
2018
Q1 | $1.02M | Buy |
4,954
+501
| +11% | +$105K | 0.14% | 98 |
|
|
2017
Q4 | $845K | Buy |
4,453
+267
| +6% | +$51.1K | 0.12% | 100 |
|
|
2017
Q3 | $811K | Buy |
4,186
+2,310
| +123% | +$418K | 0.13% | 96 |
|
|
2017
Q2 | $327K | Buy |
1,876
+239
| +15% | +$40.1K | 0.07% | 161 |
|
|
2017
Q1 | $279K | Buy |
1,637
+210
| +15% | +$32.1K | 0.08% | 171 |
|
|
2016
Q4 | $201K | Buy |
+1,427
| New | +$210K | 0.05% | 194 |
|
Other funds holding TMO
Lido Advisors's TMO Position: Q2 2026 in Review
Lido Advisors increased its Thermo Fisher Scientific (TMO) stake by 7.8% in Q2 2026, buying an estimated $1.5M and bringing the position to 43,094 shares worth $21.6M. The position accounts for 0.06% of the portfolio, ranked #215.
Lido Advisors first reported a position in TMO in Q4 2016 and has held it in 39 quarters since. The position peaked at $22.9M in Q4 2025. 2,613 funds tracked by Wall St. Rank hold TMO as of Q2 2026.
- Lido Advisors held 43,094 shares of Thermo Fisher Scientific worth $21.6M as of Q2 2026.
- Lido Advisors bought 3,116 Thermo Fisher Scientific shares in Q2 2026, an estimated $1.5M.
- Thermo Fisher Scientific made up 0.06% of Lido Advisors's portfolio in Q2 2026, its #215 holding.
- Lido Advisors first reported a position in Thermo Fisher Scientific in Q4 2016 and has held it in 39 quarters since.
- Lido Advisors's Thermo Fisher Scientific position peaked at $22.9M in Q4 2025.
- 2,613 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.
Based on Lido Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.